199 related articles for article (PubMed ID: 31550853)
1. [Targeted therapy for malignant peripheral nerve sheath tumor: translational research and clinical application].
Liao ZC; Zhang C; Liu XY; Ren ZW; Xu J; Zhang CZ; Yang Y; Zhu Z; Yang JL
Zhonghua Zhong Liu Za Zhi; 2019 Sep; 41(9):648-653. PubMed ID: 31550853
[TBL] [Abstract][Full Text] [Related]
2. Malignant Peripheral Nerve Sheath Tumors.
Durbin AD; Ki DH; He S; Look AT
Adv Exp Med Biol; 2016; 916():495-530. PubMed ID: 27165368
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors.
Endo M; Yamamoto H; Setsu N; Kohashi K; Takahashi Y; Ishii T; Iida K; Matsumoto Y; Hakozaki M; Aoki M; Iwasaki H; Dobashi Y; Nishiyama K; Iwamoto Y; Oda Y
Clin Cancer Res; 2013 Jan; 19(2):450-61. PubMed ID: 23209032
[TBL] [Abstract][Full Text] [Related]
4. Malignant peripheral nerve sheath tumor: models, biology, and translation.
Somatilaka BN; Sadek A; McKay RM; Le LQ
Oncogene; 2022 Apr; 41(17):2405-2421. PubMed ID: 35393544
[TBL] [Abstract][Full Text] [Related]
5. Targeting of AKT/ERK/CTNNB1 by DAW22 as a potential therapeutic compound for malignant peripheral nerve sheath tumor.
Li XX; Zhang SJ; Chiu AP; Lo LH; Huang J; Rowlands DK; Wang J; Keng VW
Cancer Med; 2018 Sep; 7(9):4791-4800. PubMed ID: 30112810
[TBL] [Abstract][Full Text] [Related]
6. Combinatorial therapeutic targeting of BMP2 and MEK-ERK pathways in NF1-associated malignant peripheral nerve sheath tumors.
Ahsan S; Ge Y; Tainsky MA
Oncotarget; 2016 Aug; 7(35):57171-57185. PubMed ID: 27494873
[TBL] [Abstract][Full Text] [Related]
7. Malignant peripheral nerve sheath tumors.
Farid M; Demicco EG; Garcia R; Ahn L; Merola PR; Cioffi A; Maki RG
Oncologist; 2014 Feb; 19(2):193-201. PubMed ID: 24470531
[TBL] [Abstract][Full Text] [Related]
8. The promise of signal transduction in genetically driven sarcomas of the nerve.
Kim A; Pratilas CA
Exp Neurol; 2018 Jan; 299(Pt B):317-325. PubMed ID: 28859862
[TBL] [Abstract][Full Text] [Related]
9. Treatment of malignant peripheral nerve sheath tumors in pediatric NF1 disease.
Martin E; Flucke UE; Coert JH; van Noesel MM
Childs Nerv Syst; 2020 Oct; 36(10):2453-2462. PubMed ID: 32494969
[TBL] [Abstract][Full Text] [Related]
10.
Oppel F; Ki DH; Zimmerman MW; Ross KN; Tao T; Shi H; He S; Aster JC; Look AT
Dis Model Mech; 2020 Aug; 13(8):. PubMed ID: 32651197
[TBL] [Abstract][Full Text] [Related]
11. Epigenomic Reordering Induced by Polycomb Loss Drives Oncogenesis but Leads to Therapeutic Vulnerabilities in Malignant Peripheral Nerve Sheath Tumors.
Wojcik JB; Marchione DM; Sidoli S; Djedid A; Lisby A; Majewski J; Garcia BA
Cancer Res; 2019 Jul; 79(13):3205-3219. PubMed ID: 30898839
[TBL] [Abstract][Full Text] [Related]
12. Systemic Options for Malignant Peripheral Nerve Sheath Tumors.
Hassan A; Pestana RC; Parkes A
Curr Treat Options Oncol; 2021 Feb; 22(4):33. PubMed ID: 33641042
[TBL] [Abstract][Full Text] [Related]
13. Patterns of recurrence and survival in sporadic, neurofibromatosis Type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors.
Watson KL; Al Sannaa GA; Kivlin CM; Ingram DR; Landers SM; Roland CL; Cormier JN; Hunt KK; Feig BW; Ashleigh Guadagnolo B; Bishop AJ; Wang WL; Slopis JM; McCutcheon IE; Lazar AJ; Torres KE
J Neurosurg; 2017 Jan; 126(1):319-329. PubMed ID: 27035165
[TBL] [Abstract][Full Text] [Related]
14. Outcome and prognostic factors in pediatric malignant peripheral nerve sheath tumors: An analysis of the European Pediatric Soft Tissue Sarcoma Group (EpSSG) NRSTS-2005 prospective study.
van Noesel MM; Orbach D; Brennan B; Kelsey A; Zanetti I; de Salvo GL; Gaze MN; Craigie RJ; McHugh K; Francotte N; Collini P; Bisogno G; Casanova M; Ferrari A
Pediatr Blood Cancer; 2019 Oct; 66(10):e27833. PubMed ID: 31241238
[TBL] [Abstract][Full Text] [Related]
15. Malignant peripheral nerve sheath tumor of the maxilla: Case report and review of the literature with emphasis on its poor prognosis.
Oh KY; Hong SD
Oral Oncol; 2022 Dec; 135():106211. PubMed ID: 36257181
[TBL] [Abstract][Full Text] [Related]
16. Non-cytotoxic systemic treatment in malignant peripheral nerve sheath tumors (MPNST): A systematic review from bench to bedside.
Martin E; Lamba N; Flucke UE; Verhoef C; Coert JH; Versleijen-Jonkers YMH; Desar IME
Crit Rev Oncol Hematol; 2019 Jun; 138():223-232. PubMed ID: 31092379
[TBL] [Abstract][Full Text] [Related]
17. Targeting group I p21-activated kinases to control malignant peripheral nerve sheath tumor growth and metastasis.
Semenova G; Stepanova DS; Dubyk C; Handorf E; Deyev SM; Lazar AJ; Chernoff J
Oncogene; 2017 Sep; 36(38):5421-5431. PubMed ID: 28534510
[TBL] [Abstract][Full Text] [Related]
18. Genomic and molecular characterization of malignant peripheral nerve sheath tumor identifies the IGF1R pathway as a primary target for treatment.
Yang J; Ylipää A; Sun Y; Zheng H; Chen K; Nykter M; Trent J; Ratner N; Lev DC; Zhang W
Clin Cancer Res; 2011 Dec; 17(24):7563-73. PubMed ID: 22042973
[TBL] [Abstract][Full Text] [Related]
19. The Role of Polycomb Repressive Complex in Malignant Peripheral Nerve Sheath Tumor.
Zhang X; Murray B; Mo G; Shern JF
Genes (Basel); 2020 Mar; 11(3):. PubMed ID: 32182803
[TBL] [Abstract][Full Text] [Related]
20. Current treatment options for malignant peripheral nerve sheath tumors.
Bradford D; Kim A
Curr Treat Options Oncol; 2015 Mar; 16(3):328. PubMed ID: 25777573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
